Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AgfiledCriticalNovartis Ag
Priority claimed from PCT/IB2014/059695external-prioritypatent/WO2014141104A1/en
Publication of MA38479A1publicationCriticalpatent/MA38479A1/en
Publication of MA38479B1publicationCriticalpatent/MA38479B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
L'invention concerne également des compositions contenant un composé de formule (i) et l'utilisation de ces composés dans l'inhibition de protéines idh mutantes ayant une activité néomorphe. L'invention concerne en outre l'utilisation d'un composé de formule (i) dans le traitement de maladies ou de troubles associés à ces protéines idh mutante, comprenant, sans s'y limiter, des troubles de la prolifération cellulaire, comme le cancer.The invention also relates to compositions containing a compound of formula (i) and the use of these compounds in the inhibition of mutant idh proteins having neomorphous activity. The invention further relates to the use of a compound of formula (i) in the treatment of diseases or disorders associated with such mutant idh proteins, including, but not limited to, cell proliferation disorders, such as Cancer.
MA38479A2013-03-142014-03-12
3-pyrimidin-4-yl-oxazolidin-2-ones as mutant idh inhibitors
MA38479B1
(en)